- Home
- Viscosupplementation Market
Global Viscosupplementation Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-565 | No of pages: 496 | Format:
Global viscosupplementation market is projected to register a substantial CAGR of 8.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2029.
Market Segmentation:
Global viscosupplementation market, By Source (animal origin and non-animal origin), Age Group (geriatric and adults), Injection (single injection, three injections, and five injections), Molecular Weight (intermediate molecular weight, low molecular weight, and high molecular weight), End User (hospital, orthopedic clinics, ambulatory care centers, and others), Distribution Channel (direct tender and retail sales), Countries (U.S., Canada, Mexico, Panama, Jamaica, and the Dominican Republic, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Austria, Hungary, Lithuania, Norway, Ireland, and the rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Malaysia, Taiwan, Indonesia, Philippines, and rest of Asia-Pacific, Saudi Arabia, UAE, Egypt, Israel, South Africa, Kuwait, and rest of the Middle East and Africa, Brazil, Argentina, Peru, Colombia, Chile, Ecuador, Uruguay, Venezuela, Bolivia, Paraguay, Trinidad and Tobago, Curaao, and the rest of South America) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the Global viscosupplementation market are:
Rising geriatric population
Increasing risk of osteoporosis and osteoarthritis
Market Segmentation:
Global viscosupplementation market is categorized into six notable segments: source, age group, molecular weight, injection, end user, and distribution channel.
On the basis of source, the global viscosupplementation market is segmented into the animal origin and non-animal origin
On the basis of molecular weight, the global viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight
On the basis of injection, the global viscosupplementation market is segmented into single injection, three injections, and five injections
On the basis of age group, the global viscosupplementation market is segmented into geriatric and adults
On the basis of end-user, the global viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care centers, and others
On the basis of distribution channel, the global viscosupplementation market is segmented into direct tender and retail sales
Market Players:
The key market players operating in the global viscosupplementation market are listed below:
Anika Therapeutics, Inc.
SEIKAGAKU CORPORATION
Bioventus
Fidia Farmaceutici S.P.A
Ferring B.V
sanofi-aventis U.S. LLC
Zimmer Biomet
OrthogenRx, Inc. (a subsidiary of AVNS)
APTISSEN
Johnson & Johnson Services, Inc.
LG Chem.
Viatris Inc.
IBSA Institut Biochimique SA
Ortobrand International
TRB CHEMEDICA SA
Teva Pharmaceutical Industries Ltd.
Lifecore (a subsidiary of Landec Corporation)
VIRCHOW BIOTECH
Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals)
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 61
1.1 OBJECTIVES OF THE STUDY 61
1.2 MARKET DEFINITION 61
1.3 OVERVIEW OF GLOBAL VISCOSUPPLEMENTATION MARKET 61
1.4 CURRENCY AND PRICING 63
1.5 LIMITATIONS 63
1.6 MARKETS COVERED 64
2 MARKET SEGMENTATION 67
2.1 MARKETS COVERED 67
2.2 GEOGRAPHICAL SCOPE 68
2.3 YEARS CONSIDERED FOR THE STUDY 69
2.4 DBMR TRIPOD DATA VALIDATION MODEL 70
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.6 MULTIVARIATE MODELLING 74
2.7 MARKET APPLICATION COVERAGE GRID 75
2.8 SOURCE LIFELINE CURVE 76
2.9 DBMR MARKET POSITION GRID 77
2.10 VENDOR SHARE ANALYSIS 78
2.11 SECONDARY SOURCES 79
2.12 ASSUMPTIONS 79
3 EXECUTIVE SUMMARY 80
4 PREMIUM INSIGHT 84
4.1 PESTEL 86
4.2 PORTER'S FIVE FORCES MODEL 87
5 EPIDEMIOLOGY 88
6 INDUSTRIAL INSIGHTS 89
7 PIPELINE ANALYSIS FOR GLOBAL VISCOSUPPLEMENTATION MARKET 91
8 GLOBAL VISCOSUPPLEMENTATION MARKET: REGULATIONS 92
9 MARKET OVERVIEW 95
9.1 DRIVERS 97
9.1.1 RISING GERIATRIC POPULATION 97
9.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS 97
9.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION 98
9.1.4 LOW PRODUCTION COST OF VISCOSUPPLEMENTATION PRODUCTS 98
9.2 RESTRAINTS 98
9.2.1 LACK OF TECHNICAL EXPERTISE 98
9.2.2 PRODUCT RECALL PROCEDURES 99
9.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION 99
9.3 OPPORTUNITIES 99
9.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA) 99
9.3.2 RISING HEALTHCARE INFRASTRUCTURE 100
9.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES 100
9.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT 101
9.4 CHALLENGES 101
9.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION 101
9.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION 102
10 GLOBAL VISCOSUPPLEMENTATION MARKET, BY SOURCE 103
10.1 OVERVIEW 104
10.2 NON-ANIMAL ORIGIN 106
10.2.1 ORTHOVISC 108
10.2.2 EUFLEXXA 108
10.2.3 MONOVISC 108
10.2.4 DUROLANE 108
10.2.5 GEL-ONE 109
10.2.6 SUPARTZ 109
10.2.7 GELSYN-3 109
10.2.8 CINGAL 109
10.2.9 SULPLASYN 109
10.2.10 VISCOSEAL 109
10.2.11 OSTEONIL 109
10.2.12 OTHERS 109
10.3 ANIMAL ORIGIN 109
10.3.1 HYLAN G-F 20 110
10.3.2 SYNVIC ONE 111
10.3.3 SYNVIC 111
10.3.4 OTHERS 111
10.3.5 HYALURONANS 111
10.3.6 HYALGAN 112
10.3.7 OTHERS 112
11 GLOBAL VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT 113
11.1 OVERVIEW 114
11.2 INTERMEDIATE MOLECULAR WEIGHT 116
11.2.1 ORTHOVISC 117
11.2.2 EUFLEXXA 117
11.2.3 MONOVISC 118
11.2.4 DUROLANE 118
11.2.5 VISCOSEAL 118
11.2.6 OSTEONIL 118
11.2.7 OTHERS 118
11.3 LOW MOLECULAR WEIGHT 118
11.3.1 HYLAGAN 119
11.3.2 SUPARTZ 119
11.3.3 GELSYN-3 119
11.3.4 CINGAL 119
11.3.5 SULPLASYN 120
11.3.6 OTHERS 120
11.4 HIGH MOLECULAR WEIGHT 120
11.4.1 SYNVIC ONE 121
11.4.2 SYNVIC 121
11.4.3 OTHERS 121
12 GLOBAL VISCOSUPPLEMENTATION MARKET, BY INJECTION 122
12.1 OVERVIEW 123
12.2 SINGLE INJECTION 125
12.3 THREE INJECTION 126
12.4 FIVE INJECTION 127
13 GLOBAL VISCOSUPPLEMENTATION MARKET, BY AGE GROUP 128
13.1 OVERVIEW 129
13.2 ADULTS 131
13.3 GERIATRIC 132
14 GLOBAL VISCOSUPPLEMENTATION MARKET, BY END USER 133
14.1 OVERVIEW 134
14.2 HOSPITALS 136
14.3 ORTHOPEDIC CLINICS 137
14.4 AMBULATORY CARE CENTERS 138
14.5 OTHERS 139
15 GLOBAL VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL 140
15.1 OVERVIEW 141
15.2 RETAIL SALES 143
15.3 DIRECT TENDER 144
16 GLOBAL VISCOSUPPLEMENTATION MARKET, BY REGION 145
16.1 OVERVIEW 146
16.2 NORTH AMERICA 151
16.2.1 U.S. 160
16.2.2 CANADA 165
16.2.3 MEXICO 170
16.2.4 PANAMA 175
16.2.5 JAMAICA 180
16.2.6 DOMINICAN REPUBLIC 184
16.3 EUROPE 188
16.3.1 GERMANY 197
16.3.2 FRANCE 202
16.3.3 U.K. 207
16.3.4 ITALY 212
16.3.5 RUSSIA 217
16.3.6 SPAIN 221
16.3.7 TURKEY 226
16.3.8 NETHERLANDS 231
16.3.9 SWITZERLAND 236
16.3.10 POLAND 241
16.3.11 HUNGARY 247
16.3.12 AUSTRIA 253
16.3.13 NORWAY 258
16.3.14 IRELAND 263
16.3.15 LITHUANIA 268
16.3.16 REST OF EUROPE 273
16.4 ASIA-PACIFIC 274
16.4.1 CHINA 284
16.4.2 INDIA 289
16.4.3 JAPAN 294
16.4.4 AUSTRALIA 298
16.4.5 MALAYSIA 303
16.4.6 THAILAND 309
16.4.7 SINGAPORE 314
16.4.8 SOUTH KOREA 319
16.4.9 INDONESIA 324
16.4.10 PHILIPPINES 330
16.4.11 TAIWAN 336
16.4.12 VIETNAM 342
16.4.13 REST OF ASIA-PACIFIC 347
16.5 SOUTH AMERICA 348
16.5.1 BRAZIL 357
16.5.2 COLOMBIA 361
16.5.3 ARGENTINA 367
16.5.4 CHILE 371
16.5.5 ECUADOR 376
16.5.6 URUGUAY 381
16.5.7 PERU 386
16.5.8 VENEZUELA 390
16.5.9 BOLIVIA 395
16.5.10 PARAGUAY 399
16.5.11 TRINIDAD AND TOBAGO 403
16.5.12 CURAAO 407
16.5.13 REST OF SOUTH AMERICA 411
16.6 MIDDLE EAST AND AFRICA 412
16.6.1 SOUTH AFRICA 421
16.6.2 EGYPT 426
16.6.3 SAUDI ARABIA 431
16.6.4 U.A.E 437
16.6.5 ISRAEL 442
16.6.6 KUWAIT 447
16.6.7 REST OF MIDDLE EAST AND AFRICA 452
17 GLOBAL VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE 453
17.1 COMPANY SHARE ANALYSIS: GLOBAL 453
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 454
17.3 COMPANY SHARE ANALYSIS: EUROPE 455
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 456
18 SWOT ANALYSIS 457
19 COMPANY PROFILE 458
19.1 JOHNSON & JOHNSON SERVICES, INC. 458
19.1.1 COMPANY SNAPSHOT 458
19.1.2 REVENUE ANALYSIS 458
19.1.3 COMPANY SHARE ANALYSIS 459
19.1.4 PRODUCT PORTFOLIO 459
19.1.5 RECENT DEVELOPMENTS 459
19.2 BIOVENTUS 460
19.2.1 COMPANY SNAPSHOT 460
19.2.2 REVENUE ANALYSIS 460
19.2.3 COMPANY SHARE ANALYSIS 461
19.2.4 PRODUCT PORTFOLIO 461
19.2.5 RECENT DEVELOPMENTS 462
19.3 FERRING B.V. 463
19.3.1 COMPANY SNAPSHOT 463
19.3.2 COMPANY SHARE ANALYSIS 463
19.3.3 PRODUCT PORTFOLIO 463
19.3.4 RECENT DEVELOPMENT 463
19.4 SANOFI-AVENTIS U.S. LLC 464
19.4.1 COMPANY SNAPSHOT 464
19.4.2 REVENUE ANALYSIS 464
19.4.3 COMPANY SHARE ANALYSIS 465
19.4.4 PRODUCT PORTFOLIO 465
19.4.5 RECENT DEVELOPMENTS 465
19.5 ZIMMER BIOMET 466
19.5.1 COMPANY SNAPSHOT 466
19.5.2 REVENUE ANALYSIS 466
19.5.3 COMPANY SHARE ANALYSIS 467
19.5.4 PRODUCT PORTFOLIO 467
19.5.5 RECENT DEVELOPMENTS 468
19.6 SEIKAGAKU CORPORATION 469
19.6.1 COMPANY SNAPSHOT 469
19.6.2 REVENUE ANALYSIS 469
19.6.3 PRODUCT PORTFOLIO 470
19.6.4 RECENT DEVELOPMENTS 470
19.7 ANIKA THERAPEUTICS, INC. 471
19.7.1 COMPANY SNAPSHOT 471
19.7.2 REVENUE ANALYSIS 471
19.7.3 PRODUCT PORTFOLIO 472
19.7.4 RECENT DEVELOPMENTS 472
19.8 FIDIA FARMACEUTICI S.P.A 473
19.8.1 COMPANY SNAPSHOT 473
19.8.2 REVENUE ANALYSIS 473
19.8.3 PRODUCT PORTFOLIO 473
19.8.4 RECENT DEVELOPMENT 474
19.9 APTISSEN 475
19.9.1 COMPANY SNAPSHOT 475
19.9.2 PRODUCT PORTFOLIO 475
19.9.3 RECENT DEVELOPMENT 475
19.10 IBSA INSTITUT BIOCHIMIQUE SA 476
19.10.1 COMPANY SNAPSHOT 476
19.10.2 PRODUCT PORTFOLIO 476
19.10.3 RECENT DEVELOPMENT 476
19.11 LG CHEM. 477
19.11.1 COMPANY SNAPSHOT 477
19.11.2 REVENUE ANALYSIS 477
19.11.3 PRODUCT PORTFOLIO 478
19.11.4 RECENT DEVELOPMENTS 478
19.12 LIFECORE (A SUBSIDIARY OF LANDEC CORPORATION) 479
19.12.1 COMPANY SNAPSHOT 479
19.12.2 REVENUE ANALYSIS 479
19.12.3 PRODUCT PORTFOLIO 480
19.12.4 RECENT DEVELOPMENTS 480
19.13 ORTHOGENRX, INC. (A SUBSIDIARY OF AVNS) 481
19.13.1 COMPANY SNAPSHOT 481
19.13.2 REVENUE ANALYSIS 481
19.13.3 PRODUCT PORTFOLIO 481
19.13.4 RECENT DEVELOPMENTS 482
19.14.2 PRODUCT PORTFOLIO 483
19.14.3 RECENT DEVELOPMENT 483
19.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. 484
19.15.1 COMPANY SNAPSHOT 484
19.15.2 REVENUE ANALYSIS 484
19.15.3 PRODUCT PORTFOLIO 485
19.15.4 RECENT DEVELOPMENTS 485
19.16 TRB CHEMEDICA SA 486
19.16.1 COMPANY SNAPSHOT 486
19.16.2 PRODUCT PORTFOLIO 486
19.16.3 RECENT DEVELOPMENTS 487
19.17 VIATRIS INC. 488
19.17.1 COMPANY SNAPSHOT 488
19.17.2 REVENUE ANALYSIS 488
19.17.3 PRODUCT PORTFOLIO 489
19.17.4 RECENT DEVELOPMENTS 489
19.18 VIRCHOW BIOTECH 490
19.18.1 COMPANY SNAPSHOT 490
19.18.2 PRODUCT PORTFOLIO 490
19.18.3 RECENT DEVELOPMENT 490
19.19 ZUVENTUS HEALTHCARE LTD. (A SUBSIDIARY OF EMCURE PHARMACEUTICALS) 491
19.19.1 COMPANY SNAPSHOT 491
19.19.2 REVENUE ANALYSIS 491
19.19.3 PRODUCT PORTFOLIO 492
19.19.4 RECENT DEVELOPMENT 492
20 QUESTIONNAIRE 493
21 RELATED REPORTS 496
Segmentation
Short Description
Global Viscosupplementation Market, By Source (animal origin and non-animal origin), Age Group (geriatric and adults), Injection (single injection, three injections, and five injections), Molecular Weight (intermediate molecular weight, low molecular weight, and high molecular weight), End User (hospital, orthopedic clinics, ambulatory care centers, and others), Distribution Channel (direct tender and retail sales), Countries (U.S., Canada, Mexico, Panama, Jamaica, and the Dominican Republic, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Austria, Hungary, Lithuania, Norway, Ireland, and the rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Malaysia, Taiwan, Indonesia, Philippines, and rest of Asia-Pacific, Saudi Arabia, UAE, Egypt, Israel, South Africa, Kuwait, and rest of the Middle East and Africa, Brazil, Argentina, Peru, Colombia, Chile, Ecuador, Uruguay, Venezuela, Bolivia, Paraguay, Trinidad and Tobago, Curaao, and the rest of South America) Industry Trends and Forecast to 2029.
Market Definition:
The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market.
Market Segmentation:
Global viscosupplementation market is categorized into six notable segments: source, age group, molecular weight, injection, end user, and distribution channel.
On the basis of source, the global viscosupplementation market is segmented into the animal origin and non-animal origin. Animal origin is further segmented into by type, hyaluronans, by brands, hylan G-F 20, by brand, Synvisc, and Synvisc one. Hyaluronans, by brands, are further segmented into hyalgan. Non-animal origin is segmented into SULPLASYN, GEL ONE, ORTHOVISC, MONOVISC, OSTEONIL, VISCOSEAL, EUFLEXXA, DUROLANE, SUPARTZ, GELSYN-3, and CINGEAL. In 2022, the non-animal origin segment is expected to dominate the global viscosupplementation market due to the increased density of hyaluronic acid (HA). Also, it displays high resistance to intraarticular degradation
On the basis of age group, the global viscosupplementation market is segmented into geriatric and adults. In 2022, the geriatric segment is expected to dominate the global viscosupplementation market due to an increase in the population
On the basis of injection, the global viscosupplementation market is segmented into single injection, three injections, and five injections. In 2022, the single injection segment is expected to dominate the global viscosupplementation market due to high responsiveness levels to single-injection treatment and a more prominent inclination for the administration of osteoarthritis
On the basis of molecular weight, the global viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight. In 2022, the intermediate molecular weight segment is expected to dominate the global viscosupplementation market due to the molecular weight of hyaluronic acid having a major influence on its efficacy and safety for viscosupplementation in hip osteoarthritis
On the basis of end-user, the global viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care centers, and others. In 2022, the hospital segment is expected to dominate the global viscosupplementation market due to rising preferences among customers
On the basis of distribution channel, the global viscosupplementation market is segmented into direct tender and retail sales. In 2022, the direct tender segment is expected to dominate the global viscosupplementation market as it is most commonly used by research labs, pharmaceutical shops, and hospitals
Market Players
The key market players operating in the global viscosupplementation market are listed below:
Anika Therapeutics, Inc.
SEIKAGAKU CORPORATION
Bioventus
Fidia Farmaceutici S.P.A
Ferring B.V
sanofi-aventis U.S. LLC
Zimmer Biomet
OrthogenRx, Inc. (a subsidiary of AVNS)
APTISSEN
Johnson & Johnson Services, Inc.
LG Chem.
Viatris Inc.
IBSA Institut Biochimique SA
Ortobrand International
TRB CHEMEDICA SA
Teva Pharmaceutical Industries Ltd.
Lifecore (a subsidiary of Landec Corporation)
VIRCHOW BIOTECH
Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals)
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.